Welcome to our dedicated page for Biolife Solutions news (Ticker: BLFS), a resource for investors and traders seeking the latest updates and insights on Biolife Solutions stock.
BioLife Solutions, Inc. (NASDAQ: BLFS) is a developer and supplier of cell processing tools and services and bioproduction products and services for the cell and gene therapy (CGT) and broader biopharma markets. News about BLFS often centers on how its biopreservation media, CellSeal vials, hPL products, and related cell processing tools are used in clinical trials and commercial CGT therapies, as well as on portfolio changes and strategic transactions.
Investors and industry followers can use this page to track BioLife’s announcements on quarterly and annual financial results, including updates on Cell Processing revenue and the performance of its biopreservation media franchise. The company regularly reports on the contribution of customers with approved therapies, the extent of clinical trial adoption in the United States, and its use of GAAP and non-GAAP measures such as adjusted gross margin and adjusted EBITDA.
BioLife’s news flow also includes updates on portfolio streamlining and strategic moves, such as the divestiture of its evo cold chain logistics subsidiary and earlier sales of Global Cooling, SciSafe, and Custom Biogenic Systems, as well as acquisitions and investments like the PanTHERA CryoSolutions IRI cryopreservation technology and the strategic investment in Pluristyx. These items illustrate how the company is focusing on its core cell processing business while adding scientific capabilities and adjacencies.
In addition, BioLife issues press releases on corporate developments such as the opening of the Aby J. Mathew Center for Biopreservation Excellence in Bothell, Washington, and participation in healthcare and small- and mid-cap investor conferences. For readers following the CGT supply chain, this news page provides a centralized view of BioLife’s operational updates, clinical adoption metrics, strategic transactions, and investor communications over time.
BioLife Solutions (Nasdaq: BLFS) announced a new corporate brand identity, including a redesigned logo and website, aimed at better representing its expanded portfolio of bioproduction products for cell and gene therapies. The new branding reflects BioLife's mission as a leader in biopreservation tools and is designed for flexibility in digital environments. Key features of the updated website include enhanced e-commerce capabilities, a broader product catalog, improved security, and integration of previously acquired companies.
BioLife Solutions (Nasdaq: BLFS) announced the promotion of Caitlin Rice to Global Vice President, Customer Service, effective May 19, 2021. Reporting to President Dusty Tenney, Rice aims to enhance customer service initiatives supporting the evo® cold chain management system. Her prior experience as Senior Director for Commercial Support contributed to robust customer service programs. Caitlin holds degrees in public policy and law, enhancing her qualifications for this leadership role. This strategic move is expected to strengthen BioLife's position in the bioproduction sector.
BioLife Solutions (BLFS) reported record first-quarter revenue of $16.8 million, a 39% increase from $12.2 million year-over-year. The company gained 80 new customers, including 16 for its biopreservation media. The acquisition of Global Cooling Inc. is expected to contribute $40 million to $42 million to 2021 revenue, increasing overall guidance to between $106 million and $115 million. However, the company posted an operating loss of $981,000 and a net loss of $1.1 million.
BioLife Solutions (NASDAQ: BLFS) will release its Q1 2021 financial results on May 13, 2021, after market close. Following this, a conference call and live webcast will be held at 4:30 p.m. ET for an overview of the financial results and a business update. Interested parties can access the webcast on the company’s Investor Relations page or via conference call. The company specializes in bioproduction products for cell and gene therapies and the broader biopharma market.
BioLife Solutions (BLFS) has completed the acquisition of Stirling Ultracold, issuing 6,646,870 shares for 100% of Stirling's outstanding shares. Expected revenue contribution from Stirling for 2021 is $35 million to $37 million, contributing to BioLife's total projected revenue of $101 million to $110 million. Stirling will supply 100 ultra-low temperature freezers to a leading CDMO, expanding their partnership. CEO Mike Rice anticipates cross-selling opportunities with BioLife's bioproduction tools, enhancing market reach in cell and gene therapies.
BioLife Solutions, a developer of bioproduction products, has launched a new line of high capacity controlled rate freezers (HCRF) aimed at cell therapy developers. The initial shipment targets a leading cell therapy company and supports their cold chain management for allogeneic cell therapies. The new freezers enhance BioLife's product line with features such as large volume freezing, quality assurance data management, and a touch screen controller. Expected gross margins for this product line are projected in the mid to high 50% range, with average selling prices between $450,000 and $750,000.
BioLife Solutions, Inc. (NASDAQ: BLFS) has appointed Amy DuRoss and Rachel Ellingson to its board of directors. DuRoss, CEO of Vineti, brings expertise in cell and gene therapy, while Ellingson, senior VP at Zimmer Biomet, adds significant M&A experience. Both directors will support BioLife's growth strategy and enhance shareholder value. DuRoss will serve on the Audit and Compensation committees, and Ellingson will be on the Compensation and Nominating and Governance committees. These appointments come at a crucial time for the company as it seeks to expand its position in the bioproduction market.
On March 22, 2021, Stirling Ultracold announced a definitive agreement to merge with BioLife Solutions (NASDAQ: BLFS), enhancing their position in the Gene and Cell Therapy markets. Backed by the Ohio Innovation Fund, Stirling's innovative Stirling engine technology has established it as a leader in energy-efficient ultra-low temperature biorepositories. With key personnel changes, including Dusty Tenney as President and COO of BioLife, the merger aims to accelerate growth and expand market reach.
Stirling Ultracold has entered a merger agreement with BioLife Solutions (NASDAQ: BLFS) to enhance offerings for biopharma and life sciences. The merger, set to close in Q2 2021, will preserve Stirling’s brand and staff while expanding its technology portfolio.
Stirling, known for its Energy Star™ certified ULT freezers, has over 80 patents, playing a crucial role in COVID-19 vaccine storage. Both companies expect synergies that will enhance ultracold storage solutions in various medical fields, facilitating faster pharmaceutical research and advanced treatment capabilities.
BioLife Solutions (BLFS) reported financial results for Q4 and the year ended December 31, 2020, showcasing a 78% revenue increase to $14.7 million, driven by strong sales across its portfolio. The company gained 213 new direct customers and projects total revenue in 2021 between $101 million to $110 million, reflecting growth of 110% to 129%. The gross margin declined to 50% from 57% YoY. Despite a net loss of $2.1 million in Q4 2020 compared to a net income of $3 million in Q4 2019, the acquisition of Stirling Ultracold is expected to enhance product offerings and revenue streams.